Solventum (NYSE:SOLV) Upgraded to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Solventum (NYSE:SOLV) from a hold rating to a buy rating in a report released on Saturday morning,Wall Street Zen reports.

Several other research analysts have also weighed in on the company. Weiss Ratings raised Solventum from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. Stifel Nicolaus raised their price objective on Solventum from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Mizuho set a $113.00 target price on Solventum in a research note on Thursday, August 6th. UBS Group lifted their target price on Solventum from $95.00 to $101.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, BTIG Research upped their target price on Solventum from $91.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Eight investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $92.80.

Solventum Stock Performance

Shares of SOLV opened at $87.43 on Friday. Solventum has a one year low of $62.38 and a one year high of $94.16. The company has a 50-day moving average of $85.15 and a two-hundred day moving average of $76.55. The stock has a market cap of $14.88 billion, a price-to-earnings ratio of 10.69, a PEG ratio of 1.36 and a beta of 0.61. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.02 and a quick ratio of 0.74.

Solventum (NYSE:SOLV) last released its quarterly earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.64. The business had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.15 billion. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The firm’s revenue was up 2.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.69 earnings per share. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. On average, equities research analysts expect that Solventum will post 7.22 earnings per share for the current year.

Institutional Trading of Solventum

Several hedge funds and other institutional investors have recently modified their holdings of SOLV. CrossGen Wealth LLC acquired a new position in Solventum in the 4th quarter worth about $25,000. Measured Wealth Private Client Group LLC acquired a new stake in shares of Solventum during the 3rd quarter valued at about $25,000. Clearstead Trust LLC lifted its holdings in shares of Solventum by 61.0% during the 1st quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock valued at $26,000 after buying an additional 150 shares during the last quarter. CYBER HORNET ETFs LLC bought a new stake in shares of Solventum in the 2nd quarter valued at approximately $28,000. Finally, Modus Advisors LLC bought a new stake in shares of Solventum in the 4th quarter valued at approximately $30,000.

Solventum Company Profile

Solventum Corporation (NYSE:SOLV) is a global healthcare company that develops products and technologies intended to improve patient care, support healthcare professionals and increase the efficiency of healthcare delivery. The company serves hospitals, clinics, dental practices, laboratories, government agencies and other healthcare-related organizations.

Its offerings include medical and surgical products such as wound-care, skin-care, infection-prevention and surgical solutions; dental products and materials; and health information systems that support clinical documentation, coding, workflow and decision-making.